On November 16, 2020, Denovicon Therapeutics Founder & CEO, Scott Bembenek, spoke at the Global Pharma R&D AI, Data Science and Informatics Summit (PRADI 2020) on ‘Combining Machine Learning and Molecular Modeling for Enhanced Active Learning in Small-Molecule Drug Design.’
Categories
Recent Posts
- Denovicon Selected for DOE National Lab Collaboration on Quantum–Photonic Drug Discovery
- Denovicon Reports Discovery of DNT-1569: A Highly Potent and Selective Small-Molecule PARP7 Inhibitor for Immuno-Oncology
- Denovicon Introduces Quantum Physics-Driven Generative AI For Multi-Objective Optimization of Small-Molecule Drugs
- Denovicon Renewed for the 3DEXPERIENCE Lab Accelerator
- Denovicon Therapeutics Joins ARPA-H Investor Catalyst Hub Spoke Network